In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Butenafine

This article was originally published in The Tan Sheet

Executive Summary

Butenafine: Foster City, Calif.-based Penederm's topical antifungal receives approval for OTC treatment of athlete's foot in Canada, the company announces. The product will be marketed by Schering-Plough, which intends to market the fungicide under one of its brand names: Lotrimin, Tinactin or Dr. Scholl's. Penederm says the launch will take place later this year. Penederm launched the ingredient earlier this year in the U.S. as Mentax, a Rx treatment for athlete's foot, ringworm and jock itch. Schering holds U.S. OTC rights for the ingredient but a switch will not occur for several years because of the licensing agreement...





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts